Concepedia

Suk Ran Kim

SR

Statistics

Publications

3

Citations

93

H-Index

3

Active since

2017

Affiliations

Hanmi Pharmaceutical (South Korea)(Current)

Seoul National University Bundang Hospital

Sungkyunkwan University

Samsung Medical Center

Kyung Hee University

Suk Ran Kim is an author at Hanmi Pharmaceutical (South Korea) specializing in pharmacology, dose escalation therapy, and pharmacogenomics.

Publications per year

2017–2019

3

Publications

3

Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.

Tae Won Kim, Jeeyun Lee, Sang Joon Shin et al. · Journal of Clinical Oncology · 2019 · 47 citations

, , +16

Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects

Hye In Woo, Suk Ran Kim, Wooseong Huh et al. · Drug Design Development and Therapy · 2017 · 32 citations · Full text

, , +15

A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the third‐generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers

Young Su Noh, Seonghae Yoon, Suk Ran Kim et al. · Basic & Clinical Pharmacology & Toxicology · 2019 · 14 citations · Full text

, , +15

1–3 of 3